Here are the financial returns on generative AI investments at health systems, according to a Jan. 29 Deloitte report that surveyed 121 healthcare C-suite executives across the globe:
1. Too early to measure/haven’t measured: 37%
2. Moderate return on investment: 33%
3. Low return on investment: 12%
4. Significant return on investment: 10%
5. Did not invest enough to assess return: 5%
6. Not sure/can’t say: 2%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.